scholarly journals In vitro nuclear interactome of the HIV-1 Tat protein

Retrovirology ◽  
2009 ◽  
Vol 6 (1) ◽  
Author(s):  
Virginie W Gautier ◽  
Lili Gu ◽  
Niaobh O'Donoghue ◽  
Stephen Pennington ◽  
Noreen Sheehy ◽  
...  
Keyword(s):  
2000 ◽  
Vol 74 (10) ◽  
pp. 4666-4671 ◽  
Author(s):  
Hal P. Bogerd ◽  
Heather L. Wiegand ◽  
Paul D. Bieniasz ◽  
Bryan R. Cullen

ABSTRACT Transcriptional transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter element by the essential viral Tat protein requires recruitment of positive transcription elongation factor b (P-TEFb) to the viral TAR RNA target. The recruitment of P-TEFb, which has been proposed to be necessary and sufficient for activation of viral gene expression, is mediated by the highly cooperative interaction of Tat and cyclin T1, an essential component of P-TEFb, with the HIV-1 TAR element. Species, such as rodents, that encode cyclin T1 variants that are unable to support TAR binding by the Tat-cyclin T1 heterodimer are also unable to support HIV-1 Tat function. In contrast, we here demonstrate that the bovine immunodeficiency virus (BIV) Tat protein is fully able to bind to BIV TAR both in vivo and in vitro in the absence of any cellular cofactor. Nevertheless, BIV Tat can specifically recruit cyclin T1 to the BIV TAR element, and this recruitment is as essential for BIV Tat function as it is for HIV-1 Tat activity. However, because the cyclin T1 protein does not contribute to TAR binding, BIV Tat is able to function effectively in cells from several species that do not support HIV-1 Tat function. Thus, BIV Tat, while apparently dependent on the same cellular cofactor as the Tat proteins encoded by other lentiviruses, is nevertheless unique in terms of the mechanism used to recruit the BIV Tat-cyclin T1 complex to the viral LTR promoter.


2007 ◽  
Vol 5 (5) ◽  
pp. 474-483 ◽  
Author(s):  
Ann Apolloni ◽  
Luke Meredith ◽  
Andreas Suhrbier ◽  
Rosemary Kiernan ◽  
David Harrich

2000 ◽  
Vol 20 (9) ◽  
pp. 2970-2983 ◽  
Author(s):  
Dmitri Ivanov ◽  
Youn Tae Kwak ◽  
Jun Guo ◽  
Richard B. Gaynor

ABSTRACT SPT5 and its binding partner SPT4 regulate transcriptional elongation by RNA polymerase II. SPT4 and SPT5 are involved in both 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB)-mediated transcriptional inhibition and the activation of transcriptional elongation by the human immunodeficiency virus type 1 (HIV-1) Tat protein. Recent data suggest that P-TEFb, which is composed of CDK9 and cyclin T1, is also critical in regulating transcriptional elongation by SPT4 and SPT5. In this study, we analyze the domains of SPT5 that regulate transcriptional elongation in the presence of either DRB or the HIV-1 Tat protein. We demonstrate that SPT5 domains that bind SPT4 and RNA polymerase II, in addition to a region in the C terminus of SPT5 that contains multiple heptad repeats and is designated CTR1, are critical for in vitro transcriptional repression by DRB and activation by the Tat protein. Furthermore, the SPT5 CTR1 domain is a substrate for P-TEFb phosphorylation. These results suggest that C-terminal repeats in SPT5, like those in the RNA polymerase II C-terminal domain, are sites for P-TEFb phosphorylation and function in modulating its transcriptional elongation properties.


2003 ◽  
Vol 376 (7) ◽  
pp. 994-1005 ◽  
Author(s):  
Wilma Dormeyer ◽  
Alexander Dorr ◽  
Melanie Ott ◽  
Martina Schn�lzer
Keyword(s):  

Author(s):  
M C Re ◽  
G Furlini ◽  
M Vignoli ◽  
E Ramazzotti ◽  
G Roderigo ◽  
...  
Keyword(s):  

Retrovirology ◽  
2009 ◽  
Vol 6 (S2) ◽  
Author(s):  
Virginie W Gautier ◽  
Lili Gu ◽  
Niaobh O'Donoghue ◽  
Stephen Pennington ◽  
Noreen Sheehy ◽  
...  
Keyword(s):  

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Cecilia Sgadari ◽  
Giovanni Barillari ◽  
Clelia Palladino ◽  
Stefania Bellino ◽  
Brunella Taddeo ◽  
...  

Kaposi's sarcoma (KS) is a vascular tumor frequently occurring in Human Immunodeficiency Virus- (HIV-) 1-infected individuals. Our previous work indicated that the angiogenic fibroblast growth factor (FGF)-2 and the Tat protein of HIV-1, both expressed in KS lesions of HIV-infected patients, synergize at inducing angioproliferative, KS-like lesions in mice. Here we show that the development of angioproliferative lesions promoted in mice by combined Tat and FGF-2 associates with an increase in the levels of expression of the antiapoptotic Bcl-2 protein. Upregulation of Bcl-2 expression by combined FGF-2 and Tat occurs alsoin vitro, and this protects human primary endothelial cells from programmed cell death. As Bcl-2 is expressed in human KS lesions in a fashion paralleling the progression of the disease, these findings suggest a molecular mechanism by which Tat and FGF-2 cooperate in KS maintenance and progression in HIV-infected individuals.


2020 ◽  
Vol 18 ◽  
Author(s):  
Maryam-Sadat Yadavar-Nikravesh ◽  
Alireza Milani ◽  
Rouhollah Vahabpour ◽  
Mehdi Khoobi ◽  
Haleh Bakhshandeh ◽  
...  

Background: HIV-1 TAT protein is essential for regulation of viral genome transcription. The first exon of TAT protein has a fundamental role in stimulation of the extrinsic and intrinsic apoptosis pathways but its anti-HIV activity is not clear yet. Methods: In the current study, we firstly cloned the first exon of TATcoding sequence in pET-24a expression vector and then protein expression was done in the Rosetta expression host. Next, the expressed TAT protein was purified by Ni-NTA column under native conditions. After that, the protein yield was determined by Bradford kit and NanoDrop spectrophotometry. Finally, the cytotoxicity effect and anti-Scr-HIV-1 activity of the recombinant TAT protein alone and along with Tenofovir drug were assessed by MTT and ELISA, respectively. Results: The recombinant TAT protein was successfully generated in E. coli as confirmed by 13.5% SDS-PAGE and western blotting. The protein yield was ~150-200 µg/ml. In addition, the recombinant TAT protein at a certain dose with low toxicity could suppress Scr-HIV replication in the infected HeLa cells (~30%) that was comparable with a low toxic dose of Tenofovir drug (~40%). It was interesting that the recombinant TAT protein could enhance anti-HIV potency of Tenofovir drug up to 66%. Conclusion: Generally, combination of TAT protein and Tenofovir drug could significantly inhibit HIV-1 replication. It will be required to determine their mechanism of action in the next studies.


Sign in / Sign up

Export Citation Format

Share Document